Navigation Links
FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c
Date:11/6/2008

nic angina, the debilitating cardiac chest pain that affects more than nine million Americans each year," said Louis G. Lange, CV Therapeutics chairman and chief executive officer.

"Ranexa is a very well tolerated drug that can now be considered among the first drugs to be given to patients with chronic angina. Our commercial organization will actively focus on educating new and existing prescribers about these significant new labeling improvements," Lange added.

The most frequently reported adverse reactions during treatment with Ranexa in clinical trials were dizziness, headache, constipation and nausea. Complete updated prescribing information will be available at http://www.ranexa.com.

"Ranolazine may now take optimal medical therapy to an entirely new level, and may afford enhanced symptom relief," said Dr. William Boden, clinical chief, division of cardiovascular medicine, University at Buffalo Schools of Medicine & Public Health and principal investigator of the COURAGE study. "I have seen excellent safety, tolerability and symptom relief in the great majority of chronic angina patients for whom I have prescribed ranolazine," he added.

"As we have seen in the MERLIN-TIMI 36 trial and in clinical practice, patients with ischemia and angina can be at increased risk for arrhythmias and also often have diabetes. Considering its mechanism of action, established cardiovascular safety and observed reductions in arrhythmias and HbA1c, ranolazine now becomes an even more important drug in our treatment of chronic angina," said Dr. Eugene Braunwald, Distinguished Hersey Professor of Medicine at Harvard Medical School and chairman of the TIMI Study Group.

These significant new labeling changes were supported by a supplemental new drug application submitted in September 2007 that included data from the 6,560 patient MERLIN-TIMI 36 trial, which showed no adverse trend in death or arrhythm
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children
2. FDA Approves Durameds LoSEASONIQUE(R) Oral Contraceptive
3. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
4. FDA Approves Orphan Drug Status for Revolutionary Cancer Drug for Children
5. FDA Approves AstraZenecas SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
6. FDA Approves Fougeras Clotrimazole Cream USP 1%
7. FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting
8. USDA Approves Syngenta and John Deere for Broadened Biotechnology Endorsement for Corn Crop Insurance
9. Signalife Board Approves Merger
10. FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions
11. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 Earle Martin , ... today that Ellen Teplitzky, an experienced attorney specializing ... pharmaceutical industry, has joined the firm as Director ... services practice. NDA Partners provides legal services, ... testimony, to top law firms and their clients ...
(Date:10/19/2014)... , Oct. 19, 2014 NextCODE Health, which enables ... genome in real time, today announced the launch of its ... Exchange , at the American Society of Human Genetics (ASHG) ... learn more, sign up and apply for free beta access, ... features and benefits can be viewed here . ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 The report ... Market Share, Trade, Prices, Geography Trend and Forecast (2011 ... sales category, and geography and studies the major market ... North America, Europe, and Asia. , The global chocolate ... 2010.to $98.3 billion in 2016 at an estimated CAGR ...
(Date:10/18/2014)... 2014 The “Human Insulin Market- ... Acting, Premixed), Modern Human Insulin (Rapid Acting, Long ... Novomix, Tresiba, Others) - Forecast to 2018” provides ... challenges, opportunities, current market trends, and strategies impacting ... estimates and forecasts of the revenue and share ...
Breaking Biology Technology:NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5
... CITY, Calif., May 2, 2012 Genomic Health, Inc. ... (OncoMed) today announced a strategic alliance to use Next ... applied to the clinical development of OncoMed,s  novel antibody ... agreement, OncoMed will provide Genomic Health with breast, prostate, ...
... and leukocytes (white blood cells) move toward the sides ... method for treating sepsis, a systemic and often dangerous ... team of researchers at the Massachusetts Institute of Technology ... branchlike system of microfluidic channels, 20 micrometers (20 millionths ...
... Neurological Institute researchers Jorge Otero-Millan, Stephen Macknik, and Susana ... of Neuroscience in a compelling study into why ... St. Joseph,s Hospital and Medical Center in Phoenix. , ... bases of illusory motion in Akiyoshi Kitaoka,s striking visual ...
Cached Biology Technology:Genomic Health and OncoMed Announce Strategic Alliance for Biomarker Research and Discovery Using Next Generation Sequencing 2Genomic Health and OncoMed Announce Strategic Alliance for Biomarker Research and Discovery Using Next Generation Sequencing 3Genomic Health and OncoMed Announce Strategic Alliance for Biomarker Research and Discovery Using Next Generation Sequencing 4Barrow researchers unravel illusion 2
(Date:10/16/2014)... severe respiratory tract infections and worldwide claims the ... VIB and Ghent University have succeeded in developing ... virus infection. , Xavier Saelens (VIB/UGent): "We ... way for the development of a novel approach ... suffering in numerous small children and elderly people." ...
(Date:10/15/2014)... from strains of influenza virus increases with the latest ... complacent that the most substantial threats have been identified, ... arise when a new virus strain – against which ... in the human population. There have been five such ... which – the 1918 Spanish Flu – cost 50 ...
(Date:10/15/2014)... Researchers have linked increased resistance to bacterial pneumonia in ... sex hormone estrogen. , Females are naturally more resistant ... of scientists has shown that increased resistance to bacterial ... nitric oxide synthase 3 (NOS3). They also show that ... the female sex hormone estrogen. , The team, lead ...
Breaking Biology News(10 mins):New perspectives for development of an RSV vaccine 2Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
... ongoing battle against secondhand tobacco smoke. They have pioneered the ... presence of secondhand smoke and even third-hand smoke. ... of a matchbox car, the device uses polymer films to ... then records the data on an SD memory card. The ...
... Environment Meeting of the U.S. Department of Energy Joint Genome ... Walnut Creek on March 26-28, 2013. The talks will focus ... and the environment. Keynote speeches will be delivered by Eric ... global analysis of oceanic plankton ecosystems" and Chris Voigt of ...
... and his team at the University of Queensland and the University ... test to discover just how fine a detail the archerfish could ... one of two letters an ,O, or a ,C, ... versions of both letters together and recorded which letter they spat ...
Cached Biology News:Scientists create new tools for battling secondhand smoke 2Scientists create new tools for battling secondhand smoke 3Archerfish get an eye test 2
... multiple tissue panels are designed for ... genes or proteins of interest in ... on positively charged glass slides. Total ... the identical format, and cDNA from ...
XA7 B6...
... MEGAscript RNAi Kit is optimized ... mass amounts of ready-to-use dsRNA ... systems. The MEGAscript RNAi Kit ... high-yield transcription technol-ogy and includes ...
... its actuators as building blocks, Parker ... cell-level ,robotic solutions that are ideal ... the base ,system, Parker can also ... custom structures, and ,guarding., Standard ...
Biology Products: